A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

NCT06680037 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Mediated Autoimmune Disorders

Interventions

DRUG: Azercabtagene zapreleucel (azer-cel)

Sponsor

TG Therapeutics, Inc.